MX2020012063A - Sales farmaceuticas de derivados de pirimidina y metodo de tratamiento de trastornos. - Google Patents

Sales farmaceuticas de derivados de pirimidina y metodo de tratamiento de trastornos.

Info

Publication number
MX2020012063A
MX2020012063A MX2020012063A MX2020012063A MX2020012063A MX 2020012063 A MX2020012063 A MX 2020012063A MX 2020012063 A MX2020012063 A MX 2020012063A MX 2020012063 A MX2020012063 A MX 2020012063A MX 2020012063 A MX2020012063 A MX 2020012063A
Authority
MX
Mexico
Prior art keywords
pyrimidine derivatives
pharmaceutical salts
treating disorders
present disclosure
polymorphic forms
Prior art date
Application number
MX2020012063A
Other languages
English (en)
Spanish (es)
Inventor
Landon J Durak
Marianne Langston
Pradeep Kumar Sharma
Thai Hiep Nguyen
Shuanglian Li
Xiaoguang Zhang
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2020012063A publication Critical patent/MX2020012063A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2020012063A 2018-05-14 2019-05-13 Sales farmaceuticas de derivados de pirimidina y metodo de tratamiento de trastornos. MX2020012063A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671182P 2018-05-14 2018-05-14
US201862671166P 2018-05-14 2018-05-14
PCT/US2019/032002 WO2019222093A1 (en) 2018-05-14 2019-05-13 Pharmaceutical salts of pyrimidine derivatives and method of treating disorders

Publications (1)

Publication Number Publication Date
MX2020012063A true MX2020012063A (es) 2021-04-13

Family

ID=68540756

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012063A MX2020012063A (es) 2018-05-14 2019-05-13 Sales farmaceuticas de derivados de pirimidina y metodo de tratamiento de trastornos.

Country Status (11)

Country Link
US (1) US12084431B2 (enExample)
EP (2) EP4234547A3 (enExample)
JP (2) JP2021523208A (enExample)
KR (1) KR20200144579A (enExample)
CN (1) CN112313223A (enExample)
AU (1) AU2019269372A1 (enExample)
BR (1) BR112020023107A2 (enExample)
CA (1) CA3099737A1 (enExample)
MX (1) MX2020012063A (enExample)
TW (1) TWI831780B (enExample)
WO (1) WO2019222093A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020240382B2 (en) 2019-03-19 2022-08-25 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
KR20220011663A (ko) * 2019-05-22 2022-01-28 상하이 한서 바이오메디컬 컴퍼니 리미티드 인돌 유도체-함유 억제제, 이의 제조 방법 또는 이의 적용
CN111303125A (zh) * 2020-04-10 2020-06-19 天津法莫西医药科技有限公司 一种甲氧基取代吲哚-嘧啶类化合物及其制备方法
CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations
WO2023277172A1 (en) 2021-06-30 2023-01-05 Takeda Pharmaceutical Company Limited Process for preparing pharmaceutical salts of pyrimidine derivatives
EP4367116A4 (en) * 2021-07-07 2025-04-30 Crimson Biopharm Inc. Crystalline polymorphs of epidermal growth factor receptor inhibition, and compositions and methods therefor
MX2024000261A (es) * 2021-08-06 2024-03-14 Abbisko Therapeutics Co Ltd Derivado de pirimidina o piridina, metodo de preparacion del mismo y aplicacion del mismo en la industria farmaceutica.

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3788629T2 (de) 1986-03-31 1994-04-28 Rhone Poulenc Bv Neue malonsäurederivate und zusammensetzungen, die sie enthalten, zur verzögerung des pflanzenwachstums.
JP2749578B2 (ja) 1986-03-31 1998-05-13 ローヌープーラン・ネーデルランド・ベー・ベー 相乗的植物成長調節剤組成物
JPS63503070A (ja) 1986-03-31 1988-11-10 ローヌープーラン・ネーデルランド・ベー・ベー マロン酸誘導体化合物の作物収穫量を増大させるための使用
WO2000006555A1 (en) 1998-07-30 2000-02-10 American Home Products Corporation Substituted quinazoline derivatives
SK9742002A3 (en) * 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
WO2003097855A2 (en) 2002-05-14 2003-11-27 Baylor College Of Medicine Small molecule inhibitors of her2 expression
GB0311274D0 (en) * 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
JP2008510719A (ja) 2004-08-19 2008-04-10 イコス・コーポレイション Ｃｈｋ１の阻害に有用な化合物
EP1951672B1 (en) 2005-10-21 2011-05-25 Merck Sharp & Dohme Corp. Potassium channel inhibitors
PL1948180T3 (pl) 2005-11-11 2013-09-30 Boehringer Ingelheim Int Terapia skojarzona raka polegająca na podawaniu inhibitorów EGFR/HER2
TW200826843A (en) 2006-09-13 2008-07-01 Sumitomo Chemical Co Thiadiazole compound and use thereof
FR2911140B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de 2-anilino 4-heteroaryle pyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911138B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911139A1 (fr) 2007-01-05 2008-07-11 Sanofi Aventis Sa Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
CA2690334C (en) 2007-06-08 2017-02-14 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
WO2009003998A2 (en) 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Antiproliferative compounds based on 5-membered heterocycles
FR2919869B1 (fr) 2007-08-09 2009-09-25 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
JP2012517448A (ja) 2009-02-11 2012-08-02 リアクション バイオロジー コープ． 選択的キナーゼ阻害剤
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
JP5918693B2 (ja) * 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｅｇｆｒ阻害剤及び疾患の治療方法
EP2430013B1 (en) 2009-05-13 2014-10-15 Amgen Inc. Heteroaryl compounds as pikk inhibitors
US8563567B2 (en) 2009-12-30 2013-10-22 Arqule, Inc. Substituted heterocyclic compounds
WO2012020215A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
EP2710003A1 (en) 2011-05-16 2014-03-26 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
MY161925A (en) 2011-07-27 2017-05-15 Astrazeneca Ab 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
WO2013170113A1 (en) 2012-05-11 2013-11-14 Abbvie Inc. Nampt inhibitors
AR091023A1 (es) 2012-05-11 2014-12-30 Abbvie Inc Inhibidores del nampt
US20140371238A1 (en) 2013-03-13 2014-12-18 Flatley Discovery Lab Compounds and methods for the treatment of cystic fibrosis
CN104262328B (zh) 2013-09-18 2016-09-07 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
US9840517B2 (en) 2013-09-18 2017-12-12 Beijing Hanmi Pharmaceutical Co., Ltd. Compound inhibiting activities of BTK and/or JAK3 kinases
CN104860941B (zh) 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
JP2017507983A (ja) 2014-03-18 2017-03-23 アイティーオス セラペウティクス 新規な３−インドール置換誘導体、医薬組成物、および使用方法
MY186839A (en) * 2014-06-19 2021-08-25 Takeda Pharmaceuticals Co Heteroaryl compounds for kinase inhibition
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
PL3205650T3 (pl) 2014-10-11 2021-12-06 Shanghai Hansoh Biomedical Co., Ltd. Inhibitor EGFR i jego otrzymywanie i zastosowanie
TWI696617B (zh) 2015-04-28 2020-06-21 大陸商上海復尚慧創醫藥研究有限公司 特定蛋白質激酶抑制劑
CN106995437A (zh) 2016-01-22 2017-08-01 齐鲁制药有限公司 取代吲哚或吲唑嘧啶衍生物及其制备方法和用途
CN110248934B (zh) * 2016-09-12 2022-05-24 帕德罗科治疗公司 杂芳基pad4抑制剂

Also Published As

Publication number Publication date
WO2019222093A1 (en) 2019-11-21
CN112313223A (zh) 2021-02-02
EP3793993A4 (en) 2022-01-05
TWI831780B (zh) 2024-02-11
AU2019269372A1 (en) 2020-11-26
US20210309640A1 (en) 2021-10-07
TW202015687A (zh) 2020-05-01
KR20200144579A (ko) 2020-12-29
EP4234547A2 (en) 2023-08-30
JP2024051160A (ja) 2024-04-10
EP3793993A1 (en) 2021-03-24
BR112020023107A2 (pt) 2021-02-02
US12084431B2 (en) 2024-09-10
JP2021523208A (ja) 2021-09-02
EP4234547A3 (en) 2023-11-01
CA3099737A1 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
EP4234547A3 (en) Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
ZA202202097B (en) Amino pyrimidine ssao inhibitors
SA522431428B1 (ar) عملية محسّنة لتحضير مشتقات أمينو بيريميدين
ZA201801724B (en) Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
EA201790921A1 (ru) Замещенные производные 2-анилинпиримидина в качестве модуляторов egfr
PH12020500093A1 (en) Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same
SA520411120B1 (ar) مركبات وسيطة مبتكرة مفيدة لتركيب مشتقات الأمينوبيريميدين، وعملية لتحضير هذه المركبات الوسيطة، وعملية لتحضير مشتقات الأمينوبيريميدين باستخدام هذه المركبات
PH12017500488A1 (en) Compounds and compositions for modulating egfr mutant kinase activities
MX361802B (es) Compuestos de heteroarilo para la inhibicion de cinasa.
MY199124A (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
WO2010129053A8 (en) Egfr inhibitors and methods of treating disorders
TW201711997A (en) 2-arylamino pyridine, pyridine or triazine derivative, preparation method and use thereof
PH12018502289A1 (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
PH12018500736A1 (en) Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity
HK1251567A1 (zh) 用於激酶抑制的杂芳基化合物
NZ736055A (en) Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
MX2018005140A (es) Composiciones de pirimidina, composiciones ultrapuras y sales de las mismas, metodos su elaboracion y metodos para su uso en el tratamiento de enfermedades y afecciones mediadas por el receptor histaminico h4 (h4).
PH12020550228A1 (en) Epidermal growth factor receptor inhibitors
JOP20220107A1 (ar) مثبطات egfr تفارغية وطرق استخدامها
NZ742785A (en) Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine
MX2021013982A (es) Compuestos para inhibir la quinasa del egfr, metodos de preparacion y usos de los mismos.
UA124942C2 (uk) Спосіб одержання енантіомерів пірліндолу та їхніх солей
MX2019005723A (es) Inhibidor del receptor del factor de crecimiento de fibroblastos 4 (fgfr4) y metodo de preparacion y uso del mismo.
WO2019126136A3 (en) Pyrimidine compounds useful as tyrosine kinase inhibitors
HK40059047A (en) Crystalline polymorphs of bruton's tyrosine kinase inhibitors